Back to News
Market Impact: 0.3
China approves J&J's oral psoriasis pill, says drugmaker
Source: reuters.com
Company FundamentalsRegulation & LegislationAntitrust & CompetitionHealthcare & BiotechCorporate Earnings
China’s drug regulator approved Johnson & Johnson’s oral psoriasis pill, expanding its addressable market in the world’s second-largest pharma market. The approval is likely to intensify competition with peers such as Bristol Myers Squibb and AbbVie, supporting a positive near-term outlook for J&J’s China growth prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ABBV-0.30
JNJ0.60
More News
- How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
- 2 Dividend Stocks Worth Holding Forever (Including 1 Dividend King)
- Better Pharma ETF: iShares IHE vs. State Street XPH
- Simply Injectables RI Welcomes Susan McKenna, NP, as Aesthetic Injector and GLP-1 Program Lead
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Research Systems for Hedge Funds: A Pilot Design
- Weekly Update: New Reporting Features, UI Improvements, and Chat Optimizations